

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



10004118 - GAU: 1646
Dkt No. INT 004.10

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 3

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: Method for Treating Diseases with Omega
Interferon

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	IA-01	7,101,567	September 5, 2006	Sano, et al.			

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class/ Sub Class	Translation YES NO
	IB-01	WO 96/03116	8 February 1996	PCT		
	IB-02	WO 99/62501	9 December 1999	PCT		
	IB-03	WO 00/38652	6 July 2000	PCT		
	IB-04	WO 02/36072	10 May 2002	PCT		
	IB-05	1 046 399	25 October 2000	EP		
	IB-06	1 084 703	21 March 2001	EP		

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.S./

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 2 of 3

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: Method for Treating Diseases with Omega
Interferon

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	IC-01	"AGA abstracts M1143-M1741," Gastroenterology, vol. 122, 1 April 2002, pages A278-A347, XP022329236, Abstract M1454: Open-label rising-dose study of omega interferon in IFN-naïve patients with chronic hepatitis C.
	IC-02	Adolf, G.R., et al., "Human interferon- ω 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochimica et Biophysica Acta, 1089 (1991) 167-174.
	IC-03	Aulitzky, W., et al., "Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma," Journal of Clinical Oncology, vol. 7, no. 12, 1989, pages 1875-1884, XP009079027.
	IC-04	Boué, O., et al., "Antiviral and antileukolytic activity of recombinant bovine IFN- ω 1 obtained from <i>Pichia pastoris</i> ," Journal of Interferon and Cytokine Research 20:677-683 (2000).
	IC-05	Gan To Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in malignant brain tumors," Cancer & Chemotherapy, vol. 12, no.4, April 1985, pages 913-920. ABSTRACT ONLY.
	IC-06	Gappa, M., et al., "Juvenile laryngeal papillomatosis—a case report," Pneumologie, vol. 45, no. 11, November 1991, pages 936-938, XP009079028. ABSTRACT ONLY
	IC-07	Ishiwata, K., et al., "Clinical effects of the recombinant feline interferon- ω on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8): 911-917.
	IC-08	Kubes, M., et al., "Cross-species antiviral and antiproliferative activity of human interferon- ω ," Journal of Interferon Research, 14:57-59 (1994).
	IC-09	Künzi, M.S., et al., "Role of interferon-stimulated gene ISG-15 in the interferon- ω -mediated inhibition of human immunodeficiency virus replication," Journal of Interferon and Cytokine Research, 16:919-927 (1996).
	IC-10	Lee, W.M., "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology, vol. 26, September 1997, pages 89S-95S, XP000981288.
	IC-11	Marincola, F.M., et al., "Combination 1-20 therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," Journal of Clinical Oncology,

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

10004118 - GAU: 1646
Dkt No. INT 004.10

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 3 of 3

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: Method for Treating Diseases with Omega
Interferon

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
		vol. 13, no. 5, 1995, pages 1110-1122, XP009078965.
	IC-12	McHutchison, J.G., et al., "Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment," Hepatology, vol. 34, no. 4, 1 October 2001, page A333, XP004716177. ABSTRACT ONLY.
	IC-13	Plauth, M., et al, "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology, vol. 34, no. 4, 1 October 2001, page A331, XP004716169. ABSTRACT ONLY.
	IC-14	Plauth, M., et al, "Open-label study of omega interferon in previously untreated HCV-infected patients," Journal of Hepatology, vol. 36, No. Supplement 1, April 2002, page 125, XP002511882. ABSTRACT ONLY.
	IC-15	Supplementary Partial European Search Report in European Patent Application Number EP 01 99 2550 (based on PCT/US01/46137), which corresponds to USSN: 10/004,118.

Examiner: /Jegatheesan Seharaseyon/ Date Considered: 11/16/2010

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.S./